Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   3:59:57 PM EDT
590.95
-6.67 (-1.12%)
Products

FDA Approves Dupixent For Children Aged 6 Months To 5 Years With Moderate-To-Severe Atopic Dermatitis

Published: 06/07/2022 22:00 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - FDA Approves Dupixent® (dupilumab) As First Biologic Medicine for Children Aged 6 Months to 5 Years With Moderate-to-severe Atopic Dermatitis.
FDA Approves Dupixent® (dupilumab) As First Biologic Medicine for Children Aged 6 Months to 5 Years With Moderate-to-severe Atopic Dermatitis.
FDA Approves Dupixent® (dupilumab) As First Biologic Medicine for Children Aged 6 Months to 5 Years With Moderate-to-severe Atopic Dermatitis.